Residents pick up the pieces, fear toxic fallout a day after deadly China chemical blast
Residents near a blown out chemical plant in China's eastern Shandong province on Wednesday assessed the damage to their village and monitored the wind, fearful of toxic fallout from an explosion that killed at least five people a day earlier.
Black and grey smoke was still rising from the smoldering facility, as emergency services continued to tend to the site. Local officials have not yet released the results of air quality tests.
The blast happened just before noon on Tuesday at a plant operated by Shandong Youdao Chemical in the city of Gaomi, sending plumes of orange and black smoke into the sky and littering the roadside with debris for more than a kilometre.
Nineteen people were injured and six more remain missing, according to the state-run Xinhua news agency.
Yu Qianming, a 69-year-old farmer, showed Reuters roofing that had fallen in and windows that had shattered, but said nobody in his home had suffered any injuries.
Yu said he and his wife felt safe in their home as long as the wind continued to blow north, but added they had moved their grandchild elsewhere as a precaution.
Shandong Youdao Chemical was established in August 2019 in the Gaomi Renhe chemical park, according to the company's website.
The plant develops and produces chemical components for use in pesticides and pharmaceuticals, employing more than 300 people on a site of more than 47 hectares
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
8 hours ago
- National Post
Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)
Article content BEIJING & NANJING, China — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ('Biocytogen', HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. ('NJCTTQ') announced that NTB003 (formerly BCG009), a co-developed injectable drug candidate, has received the Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA). The approved indication is Thyroid Eye Disease (TED). Article content About NTB003 Injection Article content NTB003 is a second-generation fully human anti-IGF-1R monoclonal antibody co-developed by Biocytogen and Nanjing Chia Tai Tianqing. Antibody discovery and optimization were completed by Biocytogen using its proprietary RenMab™ fully human antibody discovery platform, while Nanjing Chia Tai Tianqing was responsible for CMC process development, GLP-compliant toxicology studies, and IND application. Compared with first-generation approved anti-IGF-1R therapeutics, NTB003 demonstrates enhanced molecular affinity, improved druggability, and an extended half-life. In vitro studies have shown that NTB003 exerts potent signal-blocking activity and effectively inhibits the release of hyaluronic acid (HA), indicating strong potential for further clinical development. Article content Clinical studies of teprotumumab and other investigational anti-IGF-1R biologics have demonstrated that targeting IGF-1R can deliver significant clinical benefits. These agents have shown rapid onset of therapeutic response and favorable outcomes in reducing proptosis and diplopia, improving quality of life, and lowering clinical activity scores in patients with TED. Article content Nanjing Chia Tai Tianqing will lead the clinical development and commercialization of NTB003 in China, aiming to provide an improved therapeutic option for Chinese TED patients. Biocytogen will be responsible for the global out-licensing of the product outside China. Article content About Biocytogen Article content Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice ® (RenMab ™ / RenLite ® / RenNano ® / RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit Article content Article content Article content Article content Article content Contacts Article content Biocytogen Contacts Article content Article content Article content
CTV News
9 hours ago
- CTV News
1 dead after report of shooting in southeast Edmonton: police
A 41-year-old man is dead after a report of a shooting at 16 Avenue and 65 Street SW in Edmonton on June 4, 2025. (Supplied) A man is dead after a report of a shooting in southeast Edmonton. Emergency crews were called to 16 Avenue and 65 Street SW at 12:38 a.m. on Wednesday. A 41-year-old man was treated by EMS but he died at the scene. An autopsy has been scheduled for Thursday. The investigation has now been turned over to the Edmonton Police Service homicide section. Anyone with information or video from the area is asked to contact EPS at 780-423-4567 or Crime Stoppers at 1-800-222-8477.
CTV News
10 hours ago
- CTV News
Catastrophic engine failure causes cement truck fire on Glenmore: CFD
Fire investigators say a 'catastrophic engine failure' caused an explosion that led to a cement truck catching fire on Glenmore Trail early Wednesday. At around 6:45 a.m., calls came in after a cement truck was spotted on fire in the westbound lane of Glenmore near the southbound Deerfoot Trail exit. Police said the driver was able to get out safely and tried to extinguish the fire with his fire extinguisher, but it was too big a blaze to put out. ALERT: Traffic incident on WB Glenmore Tr and Deerfoot Tr SE. #yyctraffic #yycroads — YYC Transportation (@yyctransport) June 4, 2025 Fire crews arrived shortly after and were able to extinguish the fire. No one was injured. Fire investigators said a catastrophic engine failure resulted in an explosion that led to shrapnel and debris being thrown across the road. It also caused the fire.
